

2

Docket No. G-067US03REG  
Serial No. 09/603,665In the Claims

Claims 1-78 (Canceled).

Claim 79 (previously presented): An isolated and purified polypeptide comprising a contiguous span of at least 10 amino acids shown as positions 1 to 1629 of SEQ ID NO:5.

Claim 80 (currently amended): An isolated and purified polypeptide comprising:

- a) ~~a contiguous span of at least 6-8 contiguous~~ amino acids of SEQ ID NO:5, wherein said contiguous amino acids ~~span comprises an the~~ asparagine at ~~an~~ amino acid position ~~corresponding to position~~ 1694 of SEQ ID NO:5;
- b) ~~a contiguous span of at least 6 contiguous~~ amino acids of SEQ ID NO:5, wherein said contiguous amino acids ~~span comprises a the~~ valine at ~~an~~ amino acid position ~~corresponding to position~~ 1854 of SEQ ID NO:5;
- c) ~~a contiguous span of at least 6 contiguous~~ amino acids of SEQ ID NO:5, wherein said contiguous amino acids ~~span comprises an the~~ asparagine at ~~an~~ amino acid position ~~corresponding to position~~ 1967 of SEQ ID NO:5;
- d) ~~a contiguous span of at least 6 contiguous~~ amino acids of SEQ ID NO:5, wherein said contiguous amino acids ~~span comprises a the~~ glutamic acid at ~~an~~ amino acid position ~~corresponding to position~~ 2017 of SEQ ID NO:5; or
- e) ~~a contiguous span of at least 40 contiguous~~ amino acids of SEQ ID NO: 5, wherein said contiguous amino acids ~~span comprises a the~~ glutamic acid at ~~an~~ amino acid position ~~corresponding to position~~ 2017 of SEQ ID NO:5 and ~~an~~ the alanine at ~~an~~ amino acid position ~~corresponding to position~~ 2050 of SEQ ID NO: 5.

3

Docket No. G-067US03REG  
Serial No. 09/603,665

Claim 81 (currently amended): The polypeptide of claim 80, wherein said contiguous amino acids span the asparagine at amino acid position 1694 of SEQ ID NO:5~~said contiguous span comprises an asparagine at an amino acid position corresponding to position 1694 of SEQ ID NO:5.~~

Claim 82 (currently amended): The polypeptide of claim 80, wherein said contiguous amino acids span the valine at amino acid position 1854 of SEQ ID NO:5~~wherein said contiguous span comprises a valine at an amino acid position corresponding to position 1854 of SEQ ID NO:5.~~

Claim 83 (currently amended): The polypeptide of claim 80, wherein said contiguous amino acids span the asparagine at amino acid position 1967 of SEQ ID NO:5~~wherein said contiguous span comprises an asparagine at an amino acid position corresponding to position 1967 of SEQ ID NO:5.~~

Claim 84 (currently amended): The polypeptide of claim 80, wherein said contiguous amino acids span the glutamic acid at amino acid position 2017 of SEQ ID NO:5~~wherein said contiguous span comprises a glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5.~~

Claim 85 (currently amended): The polypeptide of claim 80, wherein said contiguous amino acids span the glutamic acid at amino acid position 2017 of SEQ ID NO:5 and the alanine at amino acid position 2050 of SEQ ID NO: 5~~wherein said contiguous span comprises a glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5 and an alanine at an amino acid position corresponding to position 2050 of SEQ ID NO:5 and is at least 40 amino acids in length.~~

Claim 86 (currently amended): A composition comprising an isolated and purified polypeptide, wherein said polypeptide has an amino acid sequence comprising:

- a) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 1 to 200;
- b) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 201 to 400;

J:\GEN067.US03.REG\Amend-Resp\Amd.w.d.finality.doc/DNB/st

- c) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 401 to 600;
- d) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 601 to 800;
- e) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 801 to 1000;
- f) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 1001 to 1200;
- g) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 1201 to 1400;
- h) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 1401 to 1629;
- i) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 1694, wherein said contiguous amino acids span the asparagine at amino acid position 1694 of SEQ ID NO:5~~wherein the amino acid at position 1694 of SEQ ID NO:5 is an asparagine;~~
- j) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 1854, wherein said contiguous amino acids span the valine at amino acid position 1854 of SEQ ID NO:5~~wherein the amino acid at position 1854 of SEQ ID NO:5 is a valine;~~
- k) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 1967, wherein said contiguous amino acids span the asparagine at amino acid position 1967 of SEQ ID NO:5~~wherein the amino acid at position 1967 of SEQ ID NO:5 is an asparagine;~~
- l) at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) 2017, wherein said contiguous amino acids span the glutamic acid at amino

5

Docket No. G-067US03REG  
Serial No. 09/603,665

~~acid position 2017 of SEQ ID NO:5 wherein the amino acid at position 2017 of SEQ ID NO:5 is a glutamic acid; and~~

- m) a contiguous span of at least 40 contiguous amino acids of SEQ ID NO:5 spanning position 2050, wherein said contiguous amino acids span the glutamic acid at amino acid position 2017 of SEQ ID NO:5 and the alanine at amino acid position 2050 of SEQ ID NO: 5 ~~wherein said span comprises a glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5 and the amino acid at position 2050 of SEQ ID NO:5 is an alanine.~~

Claim 87 (previously presented): The composition of claim 86, wherein said position(s) are 1 to 200.

Claim 88 (previously presented): The composition of claim 86, wherein said position(s) are 201 to 400.

Claim 89 (previously presented): The composition of claim 86, wherein said position(s) are 401 to 600.

Claim 90 (previously presented): The composition of claim 86, wherein said position(s) are 601 to 800.

Claim 91 (previously presented): The composition of claim 86, wherein said position(s) are 801 to 1000.

Claim 92 (previously presented): The composition of claim 86, wherein said position(s) are 1001 to 1200.

J:\GEN\067.US03.REG\Amend-Resp\Amd.w-d.finality.doc/DNB/sl

6

Docket No. G-067US03REG  
Serial No. 09/603,665

Claim 93 (previously presented): The composition of claim 86, wherein said position(s) are 1201 to 1400.

Claim 94 (previously presented): The composition of claim 86, wherein said position(s) are 1401 to 1629.

Claim 95 (currently amended): The composition of claim 86, wherein said contiguous amino acids span the asparagine at amino acid position 1694 of SEQ ID NO:5 ~~position(s) is 1694.~~

Claim 96 (currently amended): The composition of claim 86, wherein said contiguous amino acids span the valine at amino acid position 1854 of SEQ ID NO:5 ~~position(s) is 1854.~~

Claim 97 (currently amended): The composition of claim 86, wherein said contiguous amino acids span the asparagine at amino acid position 1967 of SEQ ID NO:5 ~~position(s) is 1967.~~

Claim 98 (currently amended): The composition of claim 86, wherein said contiguous amino acids span the glutamic acid at amino acid position 2017 of SEQ ID NO:5 ~~position(s) is 2017.~~

Claim 99 (currently amended): The composition of claim 86, wherein said contiguous amino acids span the glutamic acid at amino acid position 2017 of SEQ ID NO:5 and the alanine at amino acid position 2050 of SEQ ID NO: 5 ~~position(s) is 2050 and said span is at least 40 amino acids in length and comprises a glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5 and an alanine corresponding to position 2050 of SEQ ID NO:5.~~

Claim 100 (previously presented): The composition of claim 86a), 86b), 86c), 86d), 86e), 86f), 86g), 86h), 86i), 86j), 86k), or 86l), wherein said polypeptide is at least 20 amino acids in length.

I:\GEN067.US03.REG\Amend-Resp\Amd.w-d.finality.doc\DNB/sl

7

Docket No. G-067US03REG  
Serial No. 09/603,665

Claim 101 (previously presented): The composition of claim 86, wherein said polypeptide is at least 50 amino acids in length.

Claim 102 (previously presented): The composition of claim 86, wherein said polypeptide is at least 100 amino acids in length.

Claim 103 (previously presented): The polypeptide of claim 79, wherein said polypeptide is recombinant.

Claim 104 (previously presented): The polypeptide of claim 86, wherein said polypeptide is recombinant.

Claim 105 (previously presented): The composition of claim 86, further comprising a physiologically acceptable carrier.

Claim 106 (previously presented): A method of making the polypeptide of claim 79 comprising the steps of:

- a) obtaining a cell that expresses said polypeptide;
- b) growing said cell under conditions suitable to produce said polypeptide; and
- c) isolating and purifying said polypeptide produced by said cell.

Claim 107 (previously presented): The method of claim 106, wherein said cell is prokaryotic.

Claim 108 (previously presented): The method of claim 106, wherein said cell is eukaryotic.

Claim 109 (previously presented): A method of making the polypeptide of claim 86 comprising the steps of:

- a) obtaining a cell that expresses said polypeptide;

J:\GEN067.US03.REG\Amend-Resp\Amd.w-d.finality.doc/DNB/sl

8

Docket No. G-067US03REG  
Serial No. 09/603,665

- b) growing said cell under conditions suitable to produce said polypeptide; and  
isolating and purifying said polypeptide produced by said cell.

Claim 110 (previously presented): The method of claim 109, wherein said cell is prokaryotic.

Claim 111 (previously presented): The method of claim 109, wherein said cell is eukaryotic.

Claim 112 (currently amended): An isolated or purified antibody that selectively binds to an epitope-containing fragment of the polypeptide of claim 79, wherein said epitope-containing fragment comprises at least six or eight consecutive amino acids ~~one amino acid corresponding to an amino acid shown at positions~~ position 1 to 1629 of SEQ ID NO:5.

Claim 113 (currently amended): The antibody of claim 112, wherein said epitope comprises ~~at least one amino acid corresponding to an amino acid shown at position~~ the amino acids shown at positions 1 to 200 of SEQ ID NO:5.

Claim 114 (currently amended): The antibody of claim 112, wherein said epitope comprises ~~the amino acids at least one amino acid corresponding to an amino acid shown at positions~~ position 201 to 400 of SEQ ID NO:5.

Claim 115 (currently amended): The antibody of claim 112, wherein said epitope comprises ~~the amino acids at least one amino acid corresponding to an amino acid shown at positions~~ position 401 to 600 of SEQ ID NO:5.

Claim 116 (currently amended): The antibody of claim 112, wherein said epitope comprises ~~the amino acids at least one amino acid corresponding to an amino acid shown at position~~ positions 601 to 800 of SEQ ID NO:5.

J:\GEN067.US03.REG\Amend-Resp\Amd.w-d.finality.doc/DNB/sl

Claim 117 (currently amended): The antibody of claim 112, wherein said epitope comprises ~~the amino acids at least one amino acid corresponding to an amino acid shown at positions position~~ 801 to 1000 of SEQ ID NO:5.

Claim 118 (currently amended): The antibody of claim 112, wherein said epitope comprises ~~the amino acids at least one amino acid corresponding to an amino acid shown at positions position~~ 1001 to 1200 of SEQ ID NO:5.

Claim 119 (currently amended): The antibody of claim 112, wherein said epitope comprises ~~the amino acids at least one amino acid corresponding to an amino acid shown at positions position~~ 1201 to 1400 of SEQ ID NO:5.

Claim 120 (currently amended): The antibody of claim 112, wherein said epitope comprises ~~the amino acids at least one amino acid corresponding to an amino acid shown at positions position~~ 1401 to 1629 of SEQ ID NO:5.

Claim 121 (currently amended): An isolated or purified antibody that selectively binds to an epitope-containing fragment of the polypeptide of claim 80, wherein said epitope comprises ~~an amino acid selected from the group consisting of:~~

- a) ~~at least 8 contiguous amino acids of SEQ ID NO:5 that span the asparagine at amino acid position 1694 of SEQ ID NO:5 an asparagine at an amino acid position corresponding to position 1694 of SEQ ID NO:5;~~
- b) ~~at least 6 contiguous amino acids of SEQ ID NO:5 that span the valine at amino acid position 1854 of SEQ ID NO:5 a valine at an amino acid position corresponding to position 1854 of SEQ ID NO:5;~~
- c) ~~at least 6 contiguous amino acids of SEQ ID NO:5 that span the asparagine at amino acid position 1967 of SEQ ID NO:5 an asparagine at an amino acid position corresponding to position 1967 of SEQ ID NO:5;~~



10

Docket No. G-067US03REG  
Serial No. 09/603,665

- d) at least 6 contiguous amino acids of SEQ ID NO:5 that span the glutamic acid at amino acid position 2017 of SEQ ID NO:5a glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5; or and
- e) at least 40 contiguous amino acids of SEQ ID NO: 5 that span the glutamic acid at amino acid position 2017 of SEQ ID NO:5 and the alanine at amino acid position 2050 of SEQ ID NO: 5a glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5 and an alanine at an amino acid position corresponding to position 2050 of SEQ ID NO:5.

Claim 122 (currently amended): The antibody of claim 121, wherein said epitope comprises at least 8 contiguous amino acids of SEQ ID NO:5 that span the asparagine at amino acid position 1694 of SEQ ID NO:5an asparagine at an amino acid position corresponding to position 1694 of SEQ ID NO:5.

Claim 123 (currently amended): The antibody of claim 121, wherein said epitope comprises at least 6 contiguous amino acids of SEQ ID NO:5 that span the valine at amino acid position 1854 of SEQ ID NO:5a valine at an amino acid position corresponding to position 1854 of SEQ ID NO:5.

Claim 124 (currently amended): The antibody of claim 121, wherein said epitope comprises an at least 6 contiguous amino acids of SEQ ID NO:5 that span the asparagine at amino acid position 1967 of SEQ ID NO:5asparagine at an amino acid position corresponding to position 1967 of SEQ ID NO:5.

Claim 125 (currently amended): The antibody of claim 121, wherein said epitope comprises at least 6 contiguous amino acids of SEQ ID NO:5 that span the glutamic acid at amino acid position 2017 of SEQ ID NO:5a glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5.

J:\GEN\067.US03.REG\Amend-Resp\Amd.w-d.finality.doc/DNB/sl

11

Docket No. G-067US03REG  
Serial No. 09/603,665

Claim 126 (currently amended): The antibody of claim 121, wherein said epitope comprises at least 40 contiguous amino acids of SEQ ID NO: 5 that span the glutamic acid at amino acid position 2017 of SEQ ID NO:5 and the alanine at amino acid position 2050 of SEQ ID NO: 5 ~~glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5 and an alanine at an amino acid position corresponding to position 2050 of SEQ ID NO:5.~~

Claim 127 (previously presented): The isolated and purified polypeptide according to claim 80, wherein said polypeptide comprises a contiguous span of at least 10 amino acids.

Claim 128 (previously presented): The polypeptide according to claim 79, wherein said polypeptide comprises SEQ ID NO:5.

Claim 129 (previously presented): The polypeptide according to claim 80, wherein said polypeptide comprises SEQ ID NO:5.

Claim 130 (previously presented): The composition according to claim 86, wherein said polypeptide comprises SEQ ID NO:5.

Claim 131 (previously presented): The method according to claim 106, wherein said polypeptide comprises SEQ ID NO:5.

Claim 132 (previously presented): The method according to claim 109, wherein said polypeptide comprises SEQ ID NO:5.

J:\GEN067.US03.REG\Amend-Resp\Amd.w-d.finality.doc/DNB/sl